Close Menu

QuantumDx

NEW YORK (GenomeWeb News) – QuantuMDx said today that it has received a £1 million ($1.6 million) grant from the UK government's Technology Strategy Board to fund a project to develop a rapid test for multi-drug resistant tuberculosis.

Korean technology and test developer Seegene this week said that it has developed a new, real-time microarray platform that it claims eliminates the "burdensome, time-consuming" steps associated with current array technologies, and is "highly applicable" to point-of-care testing.

British biotechnology firm QuantuMDx last week announced an agreement with the Genome Institute of Singapore that will see the partners develop a genetic test specific to Asian populations on QuantuMDx's nanowire array-based platform.

NEW YORK (GenomeWeb News) – The Genome Institute of Singapore and QuantuMDx today announced a collaboration to develop point-of-care diagnostic tests specifically for the Asian population.

Nanomal, a European Union-funded public-private consortium developing a handheld device for rapid, point-of-care molecular diagnosis of malaria and drug resistance, said this week that the instrument is a year ahead of schedule and will be ready for field testing later this year.

NEW YORK (GenomeWeb News) – Molecular diagnostics firm QuantuMDx said today it has bought identity testing company NorthGene in a stock and cash deal for an undisclosed amount.

QuantumDx is heading a UK-based public-private partnership to develop a chip-based molecular profiling tool for diagnosing and staging cancer, and potentially guiding oncology treatments.

NEW YORK (GenomeWeb News) – Molecular diagnostics firm QuantuMDx and its university partners will use funding from the UK's Biomedical Catalyst program to develop and integrate the company's lab-on-a-chip technology into a device for rapidly diagnosing and staging cancers.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – A*STAR Institute of Microelectronics today announced it has signed an agreement to advance QuantuMDx's DNA sequencing nanowire biosensor to the point of commercialization.

Pages

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.